NCT02584478 2023-11-08
AL3818
Advenchen Laboratories, LLC
Phase 3 Unknown
Clinical Trials
14 trialsNCT05801783 2023-04-06
A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Ovarian Cancer
Shanghai Yunying Medical Technology
Phase EARLY_PHASE1 Unknown
NCT05622890 2022-11-21
A Single-arm Clinical Trial of IMGN853 in Chinese Adult Patients With Platinum-resistant, Epithelial Ovarian Cancer
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Phase 3 Unknown
NCT05043402 2022-08-15
A Study of Navicixizumab in Patients With Platinum Resistant Ovarian Cancer
OncXerna Theraputics, Inc.
Phase 3 Unknown
NCT02033616 2022-04-25
Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Advanced Epithelial Ovarian Carcinomas
Aivita Biomedical, Inc.
Phase 2 Unknown
NCT04229615 2022-04-25
A Study of Fluzoparib±Apatinib Versus Placebo Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on First-Line Platinum-Based Chemotherapy
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Unknown
NCT04983550 2021-07-30
Efficacy and Safety of SG001 Combined With PLD in Patients With Platinum-resistant Relapsed EOC
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 2 Unknown
NCT02785250 2021-06-18
Study of DPX-Survivac Therapy in Patients With Recurrent Ovarian Cancer
ImmunoVaccine Technologies, Inc. (IMV Inc.)
Phase 1/2 Unknown
NCT04846842 2021-04-19
A Study of Oral Gimatecan in Platinum-Resistant Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer
Lee's Pharmaceutical Limited
Phase 2 Unknown
NCT04029909 2019-07-23
A Clinical Study of Gimatecan in Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer
Lee's Pharmaceutical Limited
Phase 1 Unknown
NCT02433626 2019-02-01
COTI2-101
Critical Outcome Technologies Inc.
Phase 1 Unknown
NCT02534922 2018-02-14
ProlantaOC
Oncolix, Inc.
Phase 1 Unknown
NCT02478476 2015-06-23
DNA Single Nucleotide Polymorphisms as Predictors of Toxicity
OvaGene Oncology, Inc.
Unknown
NCT02435186 2015-05-06
p53 Gene in Treatment of Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer
Shenzhen SiBiono GeneTech Co.,Ltd
Phase 2 Unknown